Pacerone and Flecainide acetate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pacerone and Flecainide acetate. Common interactions include blindness transient among females and acute myocardial infarction among males.

The phase IV clinical study analyzes what interactions people who take Pacerone and Flecainide acetate have. It is created by eHealthMe based on reports of 6 people who take Pacerone and Flecainide acetate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 01, 2022

6 people who take Pacerone and Flecainide acetate together, and have interactions are studied.


What is Pacerone?

Pacerone has active ingredients of amiodarone hydrochloride. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 2,672 Pacerone users for its effectiveness, alternative drugs and more.

What is Flecainide acetate?

Flecainide acetate has active ingredients of flecainide acetate. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 6,289 Flecainide acetate users for its effectiveness, alternative drugs and more.

Number of Pacerone and Flecainide acetate reports submitted per year:

Pacerone and Flecainide acetate drug interactions.

Common Pacerone and Flecainide Acetate drug interactions by gender *:

female:

  1. Blindness transient
  2. Gastrointestinal haemorrhage
  3. Optic nerve disorder
  4. Vision blurred

male:

  1. Acute myocardial infarction
  2. Corneal deposits
  3. Drug maladministration
  4. Dyspnoea
  5. Epididymitis
  6. Ventricular tachycardia

Common Pacerone and Flecainide Acetate drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Acute myocardial infarction

50-59:

  1. Blindness transient
  2. Epididymitis
  3. Optic nerve disorder
  4. Vision blurred

60+:

  1. Corneal deposits
  2. Dyspnoea
  3. Gastrointestinal haemorrhage

* Approximation only. Some reports may have incomplete information.

Do you take Pacerone and Flecainide acetate?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Pacerone and Flecainide acetate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Pacerone interactions:

Browse all interactions between Pacerone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Flecainide acetate interactions:

Browse all interactions between Flecainide acetate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on amiodarone hydrochloride and flecainide acetate (the active ingredients of Pacerone and Flecainide acetate, respectively), and Pacerone and Flecainide acetate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Pacerone and Flecainide acetate.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: